|
| | 
|
 | |
        
|  |
 
|
 Gilead Sciences - [Ticker: GILD] |     | | Last Trade | 71.55 | Last Trade Time | 2018-12-03 - 00:00:00 | | Variation | --0.39 (+0.99%) | Open | 72.74 | | High | 72.90 | Low | 71.52 | | Volume | 2,159,096 | Average Volume (3m) | 0 | | Yield | | Bid / Ask | 74.80 x 800 - 74.82 x 1,000 | | Former Close | 71.94 | 52 Week Range | [0.00 - 0.00] | | PER | 0.00% | EPS | 0.00 | | Ex-Dividend Date | | Dividend Payment | | | Market Capitalization | 0 | 1 Year Price-Target | 0.00 | | Note: The data may have some minutes of delay. |
| | Watch more quotes |
| Last 10 Forum Topics about Gilead Sciences: | | No topics about Gilead Sciences [GILD] have been found, but a search on the Forum for more topics related to Gilead Sciences is advised. |
|
News about Gilead Sciences [GILD]: (ordered by relevance)
| | Gilead and AWS Collaborate on Development and Delivery of New Medicines for Patients Business Wire
Gilead Sciences (NASDAQ:GILD) Has A Rock Solid Balance Sheet Nasdaq
Gilead Sciences Irish pharma unit records $1.84bn loss The Irish Times
Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS Business Wire
CSRWire - Gilead Sciences Expresses Thanks for the Researchers, Scientists and Frontline Healthcare Workers CSRwire.com
Gilead Sciences to Present at Upcoming Investor Conference Business Wire
Gilead Sciences, Inc: An Undervalued Acquisition Machine? Sick Economics
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint Yahoo Finance
Gilead (GILD) Gets EU Nod for Breast Cancer Drug, Trodelvy Yahoo Finance
Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline Business Wire
Gilead Sciences Awards Over $1.5 Million USD In Grants Supporting Communities To Help End The HIV Epidemic In Asia Pacific ACROFAN USA
Gilead Sciences' Trodelvy marketing application OK'd in Europe for breast cancer Seeking Alpha
'Inside the Innovation:' Oncology Leaders Discuss Life at CSRwire.com
Gilead Says Co's Bold Ambition Of Transforming Triple-Negative Breast Cancer Treatment To Be Highlighted With New Data At SABCS Benzinga
Gilead (GILD) Files BLA for Bulevirtide for Hepatitis Delta Virus Entrepreneur
Gilead Sciences Inc. Partners with Center for Translational Antiviral Research to Test Oral Remdesivir Variant Georgia State University News
Gilead Is A Solidly Profitable, High Dividend-Yielding Stock Seeking Alpha
Elton John AIDS Foundation and Gilead Sciences' new campaign highlights voices of those with HIV Gay Times Magazine
NRx Soars as Drug Benefits Remdesivir-Treated Covid Patients Bloomberg
Merck and Gilead Pause HIV Study out of "Abundance of Caution" BioSpace
Opinion: Why corporate philanthropy must stand against stigma Devex
Gilead to pay $745m for three oncology programmes from Arcus Biosciences PMLiVE
Gilead eyes outpatient approval for $7 billion Covid drug remdesivir - San Francisco Business Times San Francisco Business Times
AIDS Prevention Drug TRUVADA Found Obvious by Taiwan Intellectual Property Court (Gilead Sciences, Inc. v Yikang Pharmaceutical Co., Ltd.) Lexology
Breakeven On The Horizon For Integral Ad Science Holding Corp. (NASDAQ:IAS) Nasdaq
Gilead Sciences, Merck collaborate to evaluate Trodelvy in combo with Keytruda Medical Dialogues
John Watters Is The President & COO of Mandiant, Inc. (NASDAQ:MNDT) And They Just Picked Up 7.0% More Shares Nasdaq
Should You Be Adding Guaranty Federal Bancshares (NASDAQ:GFED) To Your Watchlist Today? Nasdaq
3 Dividend Stocks That Are Dirt Cheap Right Now Motley Fool
Future Outlook on Leishmaniasis Treatment Market by Forecast to 2021 to 2028 with In-depth Analysis of Leading Players ? Sanofi SA, Sequus Pharmaceuticals Inc., Paladin Labs Inc Medgadget
Gilead Sciences to Release Third Quarter 2021 Financial Results on Thursday, October 28, 2021 Business Wire
Gilead Sciences wins reversal of $1.2 bln award in patent case with Bristol Myers Reuters
At CAGR 19.7%, CAR-T Cell Therapy Market Size to hit USD GlobeNewswire
GSK aims at NASH target with $1bn-plus Arrowhead alliance - pharmaphorum
Gilead Sciences Announces Second Quarter 2021 Financial Results Business Wire
The Omicron Variant of SARS-CoV-2 has Minimal Impact on the T Cell Epitopes (Targets) Contained ... KULR-TV
Why Gilead Sciences Investors Shouldn't Give Up on Remdesivir Just Yet Motley Fool
Cystic Fibrosis Drug Market Global Analysis, Segments, Size, Share, Industry Growth & Recent Trends by EIN News
G1 Therapeutics Announces Init GuruFocus.com
Gilead: 'Cell therapy at early stages of penetration' - BioProcess Insider BioProcess Insider
European Medicines Agency Validates Gilead's Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options gilead.com
Gilead Sciences Announces VekluryŽ Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia Business Wire
1 Cancer Stock on Buyout Watch in 2022 Motley Fool
Gilead Sciences Might Return To The Glory Days Of Past Seeking Alpha
Gilead Sciences.....a Titan Reborn? | Healthcare Stocks Sick Economics
Gilead Sciences Q3 CAR T-Cell Therapy Sales Increase 51 Percent Precision Oncology News
Gilead shares positive findings for COVID-19 treatment OutSourcing-Pharma.com
Gilead's slumping COVID-19 drug takes another hit with study showing no real benefit FiercePharma
After Biden admin failed to submit FDA chief paperwork on time, hopes for a speedy confirmation vote likely dashed: report FiercePharma
Gilead Sciences Announces Steps to Expand Availability of Remdesivir in India Business Wire
Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program Business Wire
Gilead says aware of counterfeit HIV medicines being distributed in U.S. Reuters
Gilead Sciences to Release Second Quarter 2021 Financial Results on Thursday, July 29, 2021 Business Wire
Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021 Business Wire
Gilead Sciences, Inc.'s (GILD) CEO Daniel O'Day on Q3 2021 Results - Earnings Call Transcript Seeking Alpha
Gilead Sciences: At An Inflection Point (Once Again) Seeking Alpha
Here's the Key to Gilead Sciences' Q4 Earnings Beat Motley Fool
Could Moderna Take Down Gilead Sciences? Motley Fool
Gilead Sciences Seeks Approval for Twice-Annual HIV-1 Medication BioSpace
CSRWire - Gilead Launches Pharmaceutical Education Program to Increase Workplace Diversity CSRwire.com
Why Gilead Sciences Stock Jumped Today Motley Fool
Gilead Sciences considered Durham before picking Raleigh for 275-job expansion - Triangle Business Journal Triangle Business Journal
Gilead to require U.S. workers receive COVID-19 vaccine Reuters
Gilead's Veklury shows 'no antiviral effects,' small WHO study says as company stands by COVID med FiercePharma
BioNTech to buy T-cell receptor facility and platform from Gilead Sciences MarketWatch
Stocks making the biggest moves after the bell: Amazon, Twitter, Gilead Sciences & more CNBC
Gilead Sciences Completes Acquisition of MYR GmbH Business Wire
Controversial rapper DaBaby postpones multiple shows, including Milwaukee Milwaukee Journal Sentinel
Gilead, Merck begin phase 2 study of weekly two-drug HIV regimen Healio
Could mRNA make us superhuman? BBC News
Gilead Sciences Appoints Flavius Martin, MD as Executive Vice President, Research Business Wire
India axes exports of Gilead Sciences' remdesivir, plots boost to local production as COVID cases mount: reports FiercePharma
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV Yahoo Finance
Gilead Sciences to Release Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 4, 2021 Business Wire
Where Will Gilead Sciences Be in 1 Year? Motley Fool
Gilead to Present New Data at IAS 2021 Demonstrating the Company's Commitment to Advancing Innovation in HIV Research Business Wire
Gilead, Merck and others slapped with 'pay-for-delay' lawsuits over lucrative HIV and cholesterol meds FiercePharma
A Look Into Gilead Sciences Price Over Earnings Yahoo Finance
What Is The Ownership Structure Like For Gilead Sciences, Inc. (NASDAQ:GILD)? Simply Wall St
Gilead CEO Got $19 Million Pay in Blockbuster Year for Company BioSpace
Gilead to Pay Investors $1.8 Million in Fees Over Truvada Files Bloomberg Law
Gilead Sciences Announces Updated 2020 Guidance Business Wire
Gilead-Kite Oncology to Present Transformative Science From Growing Portfolio at ASCO 2021 Business Wire
I went back into the closet at work ? until I became pregnant PinkNews
Arcus' CMO Grossman jumps ship to join Gilead's cancer push - pharmaphorum
WHO calls for lower prices on Gilead drug for Covid-linked black fungus Financial Times
Gilead's Kite enters leukemia with Tecartus FDA approval, overlapping Novartis' CAR-T rival Kymriah FiercePharma
Rand Paul reveals his wife invested in remdesivir parent company early last year MarketWatch
Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion Nasdaq
Is Gilead Sciences, Inc. (GILD) Stock Over or Undervalued? InvestorsObserver
Should You Be Worried About Gilead Sciences, Inc.'s (NASDAQ:GILD) 1.4% Return On Equity? Simply Wall St
Best Legal Departments: Gilead Sciences Navigates Development of COVID-19 Treatment Amid Legal Ops Revamp | Corporate Counsel Law.com
After Gilead Sciences' Year Of Acquisitions, 2021 Is When It Becomes An Oncology Powerhouse Seeking Alpha
Gilead nixes Veklury COVID-19 trial as vaccines roll out, more convenient drugs emerge for outpatients FiercePharma
Gilead Sciences considered Atlanta before selecting Raleigh for 275-job expansion - Atlanta Business Chronicle Atlanta Business Chronicle
Gilead Expands in NC Amidst Profitable Second Quarter BioSpace
Gilead has sole rights to COVID-19 blockbuster Veklury, GAO concludes FiercePharma
Gilead guts its filgotinib plans, dealing a blow to O'Day's diversification dream FiercePharma
Gilead's Kite matches Bristol Myers with Yescarta CAR-T win in earlier lymphoma FiercePharma
Gilead's (GILD) Biktarvy Gets FDA Nod for Pediatric Patients Entrepreneur
| For more news about Gilead Sciences click here:
Gilead Sciences News |
|
Website Width:
Background image: |
|  | |
|
|
![Gilead Sciences - [Ticker: GILD] chart](http://www.tr4der.com/chart/tr4der-GILD-1-year.png)
